Asset profile
CPI-006
Unknown / undisclosed
Evidence outlook · program status
On hold (2025-12-31), as a strategic decision by the sponsor
CPI-006 (mupadolimab) is Corvus Pharmaceuticals' humanized anti-CD73 B-cell-activating antibody. Corvus's FY2025 Form 10-K (filed 2026-03-12) still carries mupadolimab as its third product candidate but states development is paused pending prioritisation of soquelitinib and ciforadenant, so this is a hold rather than a discontinuation. status_date is the fiscal-year end the filing speaks as of; the 10-K gives no decision date. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
64 competitors in this universe: 3 direct rivals (same mechanism and indication), 1 same-class, 60 same-indication; 58 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| CPI-006: this drug | Phase 3 | — | CD73 | ||
| Oleclumab | Phase 3 | Monoclonal antibody | CD73 | ||
| Uliledlimab | Phase 2/3 | Monoclonal antibody | CD73 | ||
| PT199 | Phase 1/2 | Monoclonal antibody | CD73 | ||
| ORIC-533 | Phase 1 | Small molecule | CD73 | ||
| Afatinib (Gilotrif) | Approved | Small molecule | EGFR/HER1, HER2, HER4 | ||
| Alectinib (Alecensa) | Approved | Small molecule | ALK | ||
| Alymsys (bevacizumab-Maly) | Approved | Monoclonal antibody | VEGF-A | ||
| Amivantamab | Approved | Multispecific antibody | EGFR x c-MET | ||
| Atezolizumab | Approved | Monoclonal antibody | PD-L1 | ||
| BAT1706 (Avzivi) | Approved | Monoclonal antibody | VEGF-A | ||
| BAY2927088 (Hyrnuo) | Approved | Small molecule | HER2 (ERBB2) exon 20 insertions and point mutations; also mutant-selective EGFR | ||
| Bevacizumab | Approved | Monoclonal antibody | VEGF-A, Vascular Endothelial Growth Factor Inhibitor | ||
| Bevacizumab-Awwb (MVASI) | Approved | Monoclonal antibody | VEGF-A | ||
| Binimetinib | Approved | Small molecule | MEK1/2 | ||
| Brigatinib | Approved | Small molecule | ALK |
…and 49 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.